Search

Your search keyword '"Touw, D. J."' showing total 317 results
Start Over Author "Touw, D. J."
317 results on '"Touw, D. J."'

1. Clusterpath Gaussian Graphical Modeling

Author

Touw, D. J. W., Alfons, A., Groenen, P. J. F., and Wilms, I.

Subjects
Statistics - Machine Learning, Computer Science - Machine Learning
Abstract

Graphical models serve as effective tools for visualizing conditional dependencies between variables. However, as the number of variables grows, interpretation becomes increasingly difficult, and estimation uncertainty increases due to the large number of parameters relative to the number of observations. To address these challenges, we introduce the Clusterpath estimator of the Gaussian Graphical Model (CGGM) that encourages variable clustering in the graphical model in a data-driven way. Through the use of a clusterpath penalty, we group variables together, which in turn results in a block-structured precision matrix whose block structure remains preserved in the covariance matrix. We present a computationally efficient implementation of the CGGM estimator by using a cyclic block coordinate descent algorithm. In simulations, we show that CGGM not only matches, but oftentimes outperforms other state-of-the-art methods for variable clustering in graphical models. We also demonstrate CGGM's practical advantages and versatility on a diverse collection of empirical applications., Comment: 43 pages, 11 figures

Published
2024

8. Saliva for model informed precision dosing

Author

Touw, D J, Pharmaceutical Analysis, Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE), Medicinal Chemistry and Bioanalysis (MCB), Groningen Research Institute for Asthma and COPD (GRIAC), and Biopharmaceuticals, Discovery, Design and Delivery (BDDD)

Published
2023

17. Population pharmacokinetic model and limited sampling strategy for clozapine using plasma and dried blood spot samples

Author

Geers, L. M., Cohen, D., Wehkamp, L. M., Van Hateren, K., Van Wattum, H. J., Kosterink, J. G. W., Loonen, A. J. M., Touw, D. J., PharmacoTherapy, -Epidemiology and -Economics, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Targeted Gynaecologic Oncology (TARGON), Biopharmaceuticals, Discovery, Design and Delivery (BDDD), Pharmaceutical Analysis, Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE), Groningen Research Institute for Asthma and COPD (GRIAC), Medicinal Chemistry and Bioanalysis (MCB), and Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)

Published
2020

18. Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT)

Author

Van Den Elsen S. H. J., Sturkenboom M. G. G., Akkerman O., Barkane L., Bruchfeld J., Eather G., Heysell S. K., Hurevich H., Kuksa L., Kunst H., Kuhlin J., Manika K., Moschos C., Mpagama S. G., Munoz Torrico M., Skrahina A., Sotgiu G., Tadolini M., Tiberi S., Volpato F., Van Der Werf T. S., Wilson M. R., Zuniga J., Touw D. J., Migliori G. B., Alffenaar J. -W., Microbes in Health and Disease (MHD), Biopharmaceuticals, Discovery, Design and Delivery (BDDD), Groningen Research Institute for Asthma and COPD (GRIAC), Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE), Pharmaceutical Analysis, Medicinal Chemistry and Bioanalysis (MCB), Van Den Elsen S.H.J., Sturkenboom M.G.G., Akkerman O., Barkane L., Bruchfeld J., Eather G., Heysell S.K., Hurevich H., Kuksa L., Kunst H., Kuhlin J., Manika K., Moschos C., Mpagama S.G., Munoz Torrico M., Skrahina A., Sotgiu G., Tadolini M., Tiberi S., Volpato F., Van Der Werf T.S., Wilson M.R., Zuniga J., Touw D.J., Migliori G.B., and Alffenaar J.-W.

Subjects
medicine.medical_specialty, infectious disease, lcsh:Medicine, organisation of health service, organisation of health services, law.invention, Fluoroquinolone, Moxifloxacin, Informed consent, law, Anti-Bacterial Agent, Tuberculosis, Multidrug-Resistant, medicine, Humans, Multicenter Studies as Topic, tuberculosi, Dosing, Prospective Studies, Precision Medicine, Intensive care medicine, Prospective cohort study, Clinical pharmacology, medicine.diagnostic_test, business.industry, lcsh:R, Sputum, General Medicine, Anti-Bacterial Agents, Prospective Studie, Observational Studies as Topic, Infectious Diseases, tuberculosis, Therapeutic drug monitoring, Research Design, Observational study, clinical pharmacology, Drug Monitoring, business, Human, medicine.drug, Cohort study, Fluoroquinolones
Abstract

IntroductionGlobal multidrug-resistant tuberculosis (MDR-TB) treatment success rates remain suboptimal. Highly active WHO group A drugs moxifloxacin and levofloxacin show intraindividual and interindividual pharmacokinetic variability which can cause low drug exposure. Therefore, therapeutic drug monitoring (TDM) of fluoroquinolones is recommended to personalise the drug dosage, aiming to prevent the development of drug resistance and optimise treatment. However, TDM is considered laborious and expensive, and the clinical benefit in MDR-TB has not been extensively studied. This observational multicentre study aims to determine the feasibility of centralised TDM and to investigate the impact of fluoroquinolone TDM on sputum conversion rates in patients with MDR-TB compared with historical controls.Methods and analysisPatients aged 18 years or older with sputum smear and culture-positive pulmonary MDR-TB will be eligible for inclusion. Patients receiving TDM using a limited sampling strategy (t=0 and t=5 hours) will be matched to historical controls without TDM in a 1:2 ratio. Sample analysis and dosing advice will be performed in a centralised laboratory. Centralised TDM will be considered feasible if >80% of the dosing recommendations are returned within 7 days after sampling and 100% within 14 days. The number of patients who are sputum smear and culture-negative after 2 months of treatment will be determined in the prospective TDM group and will be compared with the control group without TDM to determine the impact of TDM.Ethics and disseminationEthical clearance was obtained by the ethical review committees of the 10 participating hospitals according to local procedures or is pending (online supplementary file 1). Patients will be included after obtaining written informed consent. We aim to publish the study results in a peer-reviewed journal.Trial registration numberClinicalTrials.gov Registry (NCT03409315).

Published
2020

29. Pharmacogenetics: From Bench to Byte

Author

Swen, J J, Wilting, I, de Goede, A L, Grandia, L, Mulder, H, Touw, D J, de Boer, A, Conemans, J MH, Egberts, T CG, Klungel, O H, Koopmans, R, van der Weide, J, Wilffert, B, Guchelaar, H-J, and Deneer, V HM

Published
2008
Full Text
View/download PDF

30. Decreased haemoglobin levels are associated with lower muscle mass and strength in kidney transplant recipients

Author

Vinke, Joanna Sophia J., Wouters, Hanneke J.C.M., Stam, Suzanne P., Douwes, Rianne M., Post, Adrian, Gomes‐Neto, Antonio W., Klauw, Melanie M., Berger, Stefan P., Bakker, Stephan J.L., Annema, C, Bakker, S J L, Berger, S P, Blokzijl, H, Bodewes, F A J A, Boer, M T, Damman, K, De Borst, M H, Diepstra, A, Dijkstra, G, Douwes, R M, Eisenga, M F, Erasmus, M E, Gan, C T, Gomes‐Neto, A W, Hak, E, Hepkema, B G, Klont, F, Knobbe, T J, Kremer, D, Leuvenink, H G D, Lexmond, W S, Meijer, V E, Niesters, H G M, Pelt, L J, Pol, R A, Porte, R J, Ranchor, A V, Sanders, J S F, Schutten, J C, Siebelink, M J, Slart, R H J A, Swarte, J C, Touw, D J, Heuvel, M C, Leer‐Buter, C, Londen, M, Verschuuren, E A M, Vos, M J, Weersma, R K, De Borst, Martin H., and Eisenga, Michele F.

Abstract

Post‐transplant anaemia and reduced muscle mass and strength are highly prevalent in kidney transplant recipients (KTRs). Decreased haemoglobin levels, a marker of anaemia, could adversely affect muscle mass and strength through multiple mechanisms, among others, through diminished tissue oxygenation. We aimed to investigate the association between haemoglobin levels with muscle mass and strength in KTRs. We included stable KTRs from the TransplantLines Biobank and Cohort study with a functional graft ≥1 year post‐transplantation. Muscle mass was assessed using 24 h urinary creatinine excretion rate (CER) and bioelectrical impedance analysis (BIA). Muscle strength was assessed with a handgrip strength test using a dynamometer and, in a subgroup (n= 290), with the five‐times sit‐to‐stand (FTSTS) test. We used multivariable linear and logistic regression analyses to investigate the associations of haemoglobin levels with muscle mass and strength. In 871 included KTRs [median age 58 (interquartile range (IQR), 48–66)] years; 60% men; eGFR 51 ± 18 mL/min/1.73 m2) who were 3.5 (1.0–10.2) years post‐transplantation, the mean serum haemoglobin level was 13.9 ± 1.8 g/dL in men and 12.8 ± 1.5 g/dL in women. Lower haemoglobin levels were independently associated with a lower CER (std. β = 0.07, P= 0.01), BIA‐derived skeletal muscle mass (std. β = 0.22, P< 0.001), handgrip strength (std. β = 0.15, P< 0.001), and worse FTSTS test scores (std. β = −0.17, P= 0.02). KTRs in the lowest age‐specific and sex‐specific quartile of haemoglobin levels had an increased risk of being in the worst age‐specific and sex‐specific quartile of CER (fully adjusted OR, 2.09; 95% CI 1.15–3.77; P= 0.02), handgrip strength (fully adjusted OR, 3.30; 95% CI 1.95–5.59; P< 0.001), and FTSTS test score (fully adjusted OR, 7.21; 95% CI 2.59–20.05; P< 0.001). Low haemoglobin levels are strongly associated with decreased muscle mass and strength in KTRs. Future investigation will need to investigate whether maintaining higher haemoglobin levels may improve muscle mass and strength in KTRs.

Published
2022
Full Text
View/download PDF

31. Therapeutic drug monitoring of oral anticancer drugs - preliminary results of a prospective study

Author

Groenland, S. L., Van Eerden, R. A. G., Koolen, S. L., Moes, D. J. A. R., Desar, I. M. E., Touw, D. J., Imholz, A. L. T., Reyners, A. K. L., Gelderblom, H., van Erp, N. P., Mathijssen, R. H. J., Huitema, A. D. R., Steeghs, N., Biopharmaceuticals, Discovery, Design and Delivery (BDDD), Groningen Research Institute for Asthma and COPD (GRIAC), Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE), Pharmaceutical Analysis, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Targeted Gynaecologic Oncology (TARGON), and Medicinal Chemistry and Bioanalysis (MCB)

Published
2019

34. Abstracts of papers and posters Meeting on Pharmaceutical Sciences

Author

Coile, Jr., Russell C., Wiedhaup, K., van Bommel, Ilva, Mol, Miriam, de Vries, Michiel, Massey, E. W., Biller, J., Davis, J. N., Adams, H. P., Marler, J. R., Magnani, H. N., Schotte, A., Janssen, P. F. M., Leysen, J. E., Skrabanja, A. T. P., Flendrig, L., van Iren, F., Schrijnemakers, E. W. M., Reinhoud, P. J., Kijne, J. W., Knevelman, A., de Wit, H. J. C., de Vries, J. D., Bult, A., Beijnen, J. H., van Winden, E. C. A., Talsma, H., Crommelin, D. J. A., Storm, G., Oussoren, C., Zuidema, J., Vingerhoeds, M. H., Smit, R. H. P., Dinther, F. v., Hultermans, T., Beumer, T., Fransz, A. N., Vromans, H., Bloemhof, D. A., van Mansvelt, F. J. W., Brouwers, J. R. B. J., Raemaekers, J., Boskma, R. J., Bloemhof, H., de Graaf, S. S. N., Uges, D. R. A., Kosterink, J. G. W., de Jonge, M. W. A., Smit, E. F., Kengen, R. A. M., de Leij, L., Piers, D. A., Shochat, D., The, T. H., Luurtsema, Gert, Franssen, Eric, Visser, Geb, Jeronimus-Stratingh, Margot, Bruins, Andries, Vaalburg, Wim, Luurtsema, G., Medema, J., Elsinga, P. H., Franssen, E. J. F., Visser, G. M., Vaalburg, W., Jmker, Jan I., Uges, Donald R. A., van der Paauw, Hugo, Maas, Max, de Vos, Henk, Hettelaar, Jenny, Slolk, L. M. L., van den Brand, W., Smit, B. J., Franssen, R. M. E., Vinks, A. A. T. M. M., Touw, D. J., Heijerman, H. G. M., Danhof, M., Bakker, W., Hermans, J., Driessen G. J., Wolters R., Go I. H., Fennis J., Gribnau F. W. J., Heerdink, Eibert R., Leufkens, Hubert G., Bakker, Albert, Heerdink, E. R., Lau, H. S., Bakker, A., Porsius, A. J., Beuning, K. S., Postma-Lim, E., de Boer, A., Nagtegaal, J. E., Stecher, N., Sturkenboom, M. C. J. M., de Jong-van den Berg, L. T. W., Cornel, M. C., Stricker, B. H. Ch., Wesseling, H., van den Bemt, P. M. L. A., Kil, P. J. M., Meyboom, R. H. B., de Koning, G. H. P., Herings, Ron M. C., Stricker, Bruno H. Ch., Leufkens, Hubert G. M., Urquhart, John, de Boer, Anthonius, Sturmans, Ferd, Middeibeek, Alma, Sturkenboom, Miriam C. J. M., de Jong-van den Berg, Lolkje T. W., Lammers, M. W., Hekster, Y. A., Keyser, A., Meinardi, H., Renier, W. O., Van Lier, H., Veehof, L., Stewart, R., Mevboom-de Jong, B., Haaijer-Ruskamp, F. M., Visser, L. E., van der Velden, J., Paes, A. H. P., van Mil, J. W. F., Tromp, Th. F. J., Casparie, M. K., Kuijpers, A., Stuvt, P. M. J., Dijkers, F. W., vd Ree, C. M., Ruben, B. A., Mokkink, H. G. A., Post, D., Gubbels, J. W., Stokx, L. J., Foets, M., Florax, C., van Dijk, A., Peters, E. T. J., van der Werf, G. T., Denig, P., Boerkamp, Ellis J. C., Haaijer-Ruskamp, Flora M., Reuyl, Jan C., Versluis, Albert, van Trigtv, Anke M., de Jong- vd Berg, Lolkie T. W., Willems, Jaap, Kaldeway, Hans, Wieringa, Nicolien, Herxheimer, Andrew, Vos, Rein, Heijman, Jennifer, Rikken, Floor, Omta S. W. F., Bouter L. M., van Engelen J. M. L., Leufkens, H. G. M., Steffens, B., Thijssen, J. J. H., de Boer, D., Tissot van Patot, H. A., Leusink, J. A., de Jongh, B. M., Reuvers, Inge H., van der Galiën, Trea A., Tromp, Dick F. J., Hendrikx, N. E. H. W., van der Werf, G. Th., Vos, R., Swart, J. A. A., Haisma, H. J., Borchert, J. C. H., Versantvoort, M. W., van Steenbergen, M. J., Hennink, W. E., Wolthuis, W. N. E., van Hooff, R. J. M., Wientjes, K. J. C., Schmidt, F. J., Schoonen, A. J. M., Te Wierik, G. H. P., Eissens, A. C., Lerk, C. F., Haas, M., Iwema Bakker, W. I., Reinhoudt, D. N., Mijer, D. K. F., de Zeeuw, D., Proost, J. H., Wierda, J. M. K. H., Meijer, D. K. F., Kuipers, M., Swart, P. J., Hendriks, M. M. W. B., Kamps, J. A. A. M., Struska, B., Thomas, C., Nijenhuis, A. M., Scherphof, G. L., Swaan, Peter W., Stehouwer, Marco C., Blok, Eric J. C., Tukker, Josef J., van Dijk, J., Gorissen, H. R. M., Groot-Padberg, Y. M., Olling M., van Gelderen C. E. M., Salomons P., Barends D. M., Meulenbelt J., Rauws A. G., Craane-van Hinsberg, W. H. M., Verhoef, J. C., Junginger, H., and Boddé, H. E.

Published
1993
Full Text
View/download PDF

35. Abstracts of papers and posters Clinical Pharmacological Meeting

Author

Verhagen, C. A., Mattie, H., van Strijen, E., van Musscher, A. K. S., Leusink, J. A., Lau, H. S., de Jongh, B. M., Bras, L. J., de Boer, A., Touw, D. J., Vinks, A. A. T. M. M., Heijerman, H. G. M., Hermans, J., Bakker, W., Buikema, H., Grandiean, J. G., Oosterga, M., de Langen, C. D. J., van Gilst, W. H., de Graeff, P. A., Wesseling, H., Steurs, M. H., Kuks, P. F. M., Porsius, A. J., Smits, P., Lenders, J. W. M., Thien, Th., Chang, P. C., Bruning, T. A., van Zwieten, P. A., van der Kuy, P. -H. M., Kraaijenga, J. J., Meulendijk, A. J. M., Spek, J., Kool, M., Hoeks, A., Boudier, H. Struijker, Van Bortel, L., Rongen, G. A., Ver Donck, K., Van Belle, H., Visser, L. E., Stricker, B. H. Ch., van der Velden, J., Paes, A. H. P., Bakker, A., van Mevel, J. J. M., Dormans, T., Smits, P., Gerlag, P. G. G., van Patot, H. A. Tissot, de Jonah, B. M., Steffens, B., Thijssen, J. J. H., de Boer, D., Loonen, A. J. M., Engberink, M. H. A., Doornbos, M., Doorschot, C. H., Janknegt, R., Fabius, G. Th. J., van den Born, J. Bongaard, Guchelaar, H. -J., de Vries, E. G. E., Meijer, C., Esselink, M. T., Vellenga, E., Uges, D. R. A., Mulder, N. H., Schipper, N. G. M., Romeijn, S. G., Verhoef, J., Merkus, F. W. H. M., Peeters, P. A. M., Oosterhuis, B., Zech, K., Huber, R., Hartmann, M., Jonkman, J. H. G., Schellens, J. H. M., Ma, J., Planting, A. S. T., de Boer-Dennert, M., van der Burg, M. E. L., Stoter, G., and Verweij, J.

Published
1993
Full Text
View/download PDF

41. Rifampin levels in daily practice: the accuracy of a single measurement

Author

Vanbrabant, T. J. F., Dijkmans, A. C., den Hartigh, J., Touw, D. J., Arend, S. M., Nanomedicine & Drug Targeting, Biopharmaceuticals, Discovery, Design and Delivery (BDDD), Groningen Research Institute for Asthma and COPD (GRIAC), Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE), and Medicinal Chemistry and Bioanalysis (MCB)

Subjects
MODEL, tuberculosis, HALF-LIFE, therapeutic drug monitoring, INFECTION, UPDATE, HUMANS, MOXIFLOXACIN, IN-VITRO, POPULATION PHARMACOKINETICS, PULMONARY TUBERCULOSIS PATIENTS, serum levels, Absorption
Abstract

Background: Measurement of rifampin levels is not part of routine practice. However, low levels are associated with failure of tuberculosis treatment. The clinical relevance of serum levels in daily practice is unclear. The objective was to evaluate rifampin serum concentrations and factors associated with insufficient concentrations. Methods: Patients with at least one rifampin concentration drawn 3 hours after intake (C-3) between 2005 and 2014 were included. Data on demographic and clinical characteristics were collected, including side effects and dose adjustments. Two different criteria were used to define adequate concentrations (criterion 1: C(3 )and C-6 >= 3 mg/l; criterion 2: C-3 or C-6 >= 5 mg/l). Results: Of 63 patients, 66% and 76% had a sufficient level according to criterion 1 or 2, respectively. C(3 )exceeded C-6 in most patients, while a late maximum was significantly associated with diabetes mellitus (p = 0.003). A dose adjustment was made in 19% of cases, more frequently in patients with insufficient levels (p = 0.02) or with 2 side effects (p = 0.03). Conclusion: Rifampin levels varied but were mostly adequate and a single measurement at 3 hours after intake provided the required information in most cases, indicating that full AUC(0.24) measurements could be limited to specific situations.

Published
2018

42. De behandeling van vergiftigingen

Author

Verschueren, M V, Jansman, F G A, Touw, D J, Kramers, C, FarmacoTherapie, -Epidemiologie en -Economie, Nanomedicine & Drug Targeting, Biopharmaceuticals, Discovery, Design and Delivery, Groningen Research Institute for Asthma and COPD, Critical care, Anesthesiology, Peri-operative and Emergency medicine, and Synthesis and Analysis

Subjects
digestive, oral, and skin physiology, Journal Article, food and beverages, English Abstract
Abstract

A new guideline: 'Intoxication: initial approach in the hospital' will be published this year. This guideline sets out the latest insights on gastrointestinal decontamination in intoxication; the advice is summarized in a flowchart.- The advice is to generally administer activated charcoal, unless there are indications that the toxin will not bind to activated charcoal or that the amount of toxin that the patient has ingested is too great; in these cases gastric lavage can be considered.- Activated charcoal can be administered up to 2 hours after the ingestion of a toxic substance, unless there are contra-indications. Multiple-dose activated charcoal in combination with a laxative can be administered in cases of overdose with toxins that use the enterohepatic circulation (such as theophylline, carbamazepine, quinine, dapsone and phenobarbital).- Gastric lavage should be limited to extremely serious intoxication, when the substance has been ingested less than 1-2 hours previously.- Whole-bowel irrigation should not be performed routinely but should be limited to ingestion of toxins with sustained release or enteric coating, or for toxins that do not bind to activated charcoal.

Published
2018

47. Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients

Author

Zuur, M. A., primary, Ghimire, S., additional, Bolhuis, M. S., additional, Wessels, A. M. A., additional, van Altena, R., additional, de Lange, W. C. M., additional, Kosterink, J. G. W., additional, Touw, D. J., additional, van der Werf, T. S., additional, Akkerman, O. W., additional, and Alffenaar, J. W. C., additional

Published
2018
Full Text
View/download PDF

48. Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis

Author

Boonstra, J. M., primary, van der Elst, K. C., additional, Veringa, A., additional, Jongedijk, E. M., additional, Brüggemann, R. J., additional, Koster, R. A., additional, Kampinga, G. A., additional, Kosterink, J. G., additional, van der Werf, T. S., additional, Zijlstra, J. G., additional, Touw, D. J., additional, and Alffenaar, J. W. C., additional

Published
2017
Full Text
View/download PDF

50. Guidelines for the management of pregnancy in women with cystic fibrosis

Author

Edenborough, F P, Borgo, G, Knoop, Christiane, Lannefors, L, Mackenzie, W E, Madge, S, Morton, A M, Oxley, H C, Touw, D J, Benham, M, Johannesson, M, European Cystic Fibrosis Society, Nanomedicine & Drug Targeting, Biopharmaceuticals, Discovery, Design and Delivery (BDDD), Groningen Research Institute for Asthma and COPD (GRIAC), Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE), and Medicinal Chemistry and Bioanalysis (MCB)

Subjects
Counseling, Postnatal Care, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Cystic Fibrosis, Genetic counseling, Cystic Fibrosis -- psychology -- therapy, Genetic Counseling, Prenatal care, Guidelines, Abortion, Preconception Care, Patient Care Planning, Nursing care, Abnormalities, Drug-Induced -- prevention & control, Pregnancy, Humans, Medicine, Pediatrics, Perinatology, and Child Health, Pregnancy Complications -- psychology -- therapy, Intensive care medicine, Transplantation, business.industry, Induced, Abnormalities, Drug-Induced, Abortion, Induced, Obstetric, Prenatal Care, Organ Transplantation, Sciences bio-médicales et agricoles, Delivery, Obstetric, medicine.disease, Management, Pregnancy Complications, Breast Feeding, Drug-Induced, Pediatrics, Perinatology and Child Health, Female, Nursing Care, Nutrition Therapy, Abnormalities, business, Delivery, Breast feeding
Abstract

Women with cystic fibrosis (CF) now regularly survive into their reproductive years in good health and wish to have a baby. Many pregnancies have been reported in the literature and it is clear that whilst the outcome for the baby is generally good and some mothers do very well, others find either their CF complicates the pregnancy or is adversely affected by the pregnancy. For some, pregnancy may only become possible after transplantation. Optimal treatment of all aspects of CF needs to be maintained from the preconceptual period until after the baby is born. Clinicians must be prepared to modify their treatment to accommodate the changing physiology during pregnancy and to be aware of changing prescribing before conception, during pregnancy, after birth and during breast feeding. This supplement offers consensus guidelines based on review of the literature and experience of paediatricians, adult and transplant physicians, and nurses, physiotherapists, dietitians, pharmacists and psychologists experienced in CF and anaesthetist and obstetricians with experience of CF pregnancy. It is hoped they will provide practical guidelines helpful to the multidisciplinary CF teams caring for pregnant women with CF., Journal Article, Practice Guideline, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results